Evaluation of Derivatives of (+)-Puupehenone against Clostridioides difficile and Other Gram-Positive Bacteria.

Autor:	Johnstone MA; Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32816-2364, United States., Landgraf AD; Department of Chemistry and Biochemistry, University of Toledo, 2801 West Bancroft Street, Toledo, Ohio 43606, United States., Si A; Department of Chemistry and Biochemistry, University of Toledo, 2801 West Bancroft Street, Toledo, Ohio 43606, United States., Sucheck SJ; Department of Chemistry and Biochemistry, University of Toledo, 2801 West Bancroft Street, Toledo, Ohio 43606, United States., Self WT; Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32816-2364, United States.
Jazyk:	angličtina
Zdroj:	ACS omega [ACS Omega] 2022 Sep 09; Vol. 7 (37), pp. 33511-33517. Date of Electronic Publication: 2022 Sep 09 (Print Publication: 2022).
DOI:	10.1021/acsomega.2c04471
Abstrakt:	Patients receiving healthcare are at higher risk of acquiring healthcare-associated infections, which cause a significant number of illnesses and deaths. Most pathogens responsible for these infections are highly resistant to multiple antibiotics, prompting the need for discovery of new therapeutics to combat these evolved threats. We synthesized structural derivatives of (+)-puupehenone, a marine natural product, and observed growth inhibition of several clinically relevant Gram-positive bacteria, particularly Clostridioides difficile . The most potent compounds-(+)-puupehenone, 1 , 15 , 19 , and 20 -all inhibited C. difficile in the range of 2.0-4.0 μg/mL. Additionally, when present in the range of 1-8 μg/mL, a subset of active compounds-(+)-puupehenone, 1 , 6 , 15 , and 20 -greatly reduced the ability of C. difficile to produce exotoxins, which are required for disease in infected hosts. Our findings showcase a promising class of compounds for potential drug development against Gram-positive pathogens, such as C. difficile . Competing Interests: The authors declare no competing financial interest. (© 2022 The Authors. Published by American Chemical Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu